|1.||Itoh, Kyogo: 6 articles (11/2009 - 02/2004)|
|2.||Noguchi, Masanori: 5 articles (11/2009 - 10/2005)|
|3.||Harada, Mamoru: 4 articles (05/2015 - 10/2005)|
|4.||Shichijo, Shigeki: 4 articles (11/2009 - 02/2004)|
|5.||Slingluff, Craig L: 4 articles (05/2008 - 11/2003)|
|6.||Takedatsu, Hiroko: 4 articles (05/2007 - 02/2004)|
|7.||Neese, Patrice Y: 3 articles (05/2008 - 11/2003)|
|8.||Petroni, Gina R: 3 articles (05/2008 - 11/2003)|
|9.||Chianese-Bullock, Kimberly A: 3 articles (05/2008 - 11/2003)|
|10.||Matsueda, Satoko: 3 articles (05/2007 - 10/2005)|
|1.||Breast Neoplasms (Breast Cancer)
02/01/2008 - "E75 is safe and effective in raising a dose-dependent HER2/neu immunity in HLA-A2 and HLA-A3 NP and NN breast cancer patients. "
09/01/1999 - "These CTL lines were also cytotoxic against HLA-A2 and HLA-A3 breast cancer cells but not against normal fibroblastoid cell lines, normal epidermal cell lines, or a melanoma cell line. "
11/01/2009 - "These results suggest that this peptide could be widely applicable as a peptide vaccine for HLA-A3 supertype-, HLA-A2-, and -A24-positive cancer patients."
11/01/2009 - "We previously reported peptide vaccine candidates for HLA-A3 supertype (-A3, -A11, -A31, -A33)-positive cancer patients. "
04/01/2007 - "New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles."
02/01/2004 - "We identified new peptide vaccine candidates for HLA-A3, -A11, -A31, and -A33 positive cancer patients. "
10/01/1999 - "Of the tumor lines transfected with HLA-A3 only the human kidney tumor cell line was lysed at a level equal to the original kidney epithelial cell used to develop the clone. "
|3.||Hemochromatosis (Bronze Diabetes)
01/01/2011 - "Irish people with two HLA-A3 alleles had a high risk of hemochromatosis. "
03/01/2002 - "Most Caucasian patients with hereditary hemochromatosis (HH) are homozygous for HLA-A3 and for the C282Y mutation of the HFE gene, while a minority are compound heterozygotes for C282Y and H63D. "
01/01/2001 - "A woman who inherited C282Y also possessed HLA-A3, -B7 which is considered part of the ancestral haplotype containing the gene predisposing to hemochromatosis in Caucasians. "
06/01/1997 - "HLA-A3 was used as the marker for the hemochromatosis gene in the population studied. "
08/01/1990 - "Comparison of the two groups revealed a significantly high frequency of one 14 kb EcoRI fragment among the HLA-A3 hemochromatosis patients. "
|4.||Melanoma (Melanoma, Malignant)
02/15/2014 - "In this study, we describe a new antigenic peptide, which is presented by HLA-A3 and comprises two noncontiguous fragments of the melanoma differentiation Ag gp100(PMEL17) spliced together in the reverse order to that in which they appear in the parental protein. "
04/01/1997 - "Thus although a significant percentage of Caucasians express HLA-A3, no melanoma-associated antigenic peptide presented by this allele has yet been identified. "
04/01/1997 - "Identification of a gp100 epitope recognized by HLA-A3 restricted melanoma infiltrating lymphocytes."
05/08/1992 - "The pattern of cytotoxicity against a panel of HLA-typed melanoma cells and inhibition by (polyclonal) HLA-typing sera suggested the CD8+ CTL were restricted by HLA-A3. "
12/15/2003 - "The SQNFPGSQK peptide was also found to be associated with HLA-A3 on an additional melanoma tumor line, thus indicating that the peptide is not unique to the melanoma tumor line from which it was isolated and thus, unlikely to arise through a mutational event. "
|5.||Prostatic Neoplasms (Prostate Cancer)
05/01/2015 - "The EZH2733-741 peptide-stimulated and purified CD8(+) T cells from PBMCs of HLA-A3 supertype allele(+) prostate cancer patients showed higher cytotoxicity against HLA-A3 supertype allele-expressing LNCaP prostate cancer cells than against parental LNCaP cells. "
10/01/2005 - "Antibody blocking and cold inhibition experiments revealed that the HLA-A3 supertype-restricted cytotoxicity against prostate cancer cells could be ascribed to peptide-specific and CD8+ T cells. "
10/01/2005 - "Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles."
05/01/2015 - "These results indicate that the EZH2733-741 peptide could be a promising candidate for peptide-based immunotherapy for HLA-A3 supertype allele(+) prostate cancer patients."
05/01/2015 - "In this study, we identified an enhancer of zeste homolog (EZH) 2-derived peptide applicable for anti-cancer vaccine for prostate cancer patients with HLA-A3 supertype alleles. "
|1.||HLA-A2 Antigen (HLA A2 Antigen)
|5.||HLA-A Antigens (HLA-A)
|8.||Genetic Markers (Genetic Marker)
|10.||HLA-B7 Antigen (HLA B7 Antigen)
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
|4.||Transplantation (Transplant Recipients)